v3.25.1
Unaudited Consolidated Statements of Changes in Stockholder’s Equity - USD ($)
$ in Thousands
Preferred stock
Series A
Preferred stock
Series B
Common stock
Additional paid-in capital
Accumulated defecit
Total
Balance at Dec. 31, 2023 $ 26,211 $ (27,602) $ (1,392)
Balance (in Shares) at Dec. 31, 2023 6,000 4,308,822      
Net loss         (1,862) (1,862)
Preferential issue 787 787
Preferential issue (in Shares)     417,395      
Issue of Options (ISO/NSO) 26 26
Balance at Mar. 31, 2024 27,024 (29,464) (2,441)
Balance (in Shares) at Mar. 31, 2024 6,000 4,726,217      
Balance at Dec. 31, 2024 $ 7,435 21,022 (33,571) (5,114)
Balance (in Shares) at Dec. 31, 2024 6,000 1,600,000 5,666,781      
Net loss         (1,700) (1,700)
Shares issued for services 88 88
Shares issued for services (in Shares) 14,000 130,977      
Common Stock issued for cash 95 95
Common Stock issued for cash (in Shares)     7,017,429      
Prefunded warrants issued for cash [1] 395 395
Prefunded warrants issued for cash (in Shares) [1]      
Series B (cashless warrants) [2] 14,710 14,710
Series B (cashless warrants) (in Shares) [2]      
Expenses relating to funding (1,524) (1,524)
Conversion of Debt to Equity 1,191 1,191
Conversion of Debt to Equity (in Shares)     2,629,040      
Shares issued for acquisition (Contingent Consideration) 400 400
Shares issued for acquisition (Contingent Consideration) (in Shares)     594,129      
Issue of Options (ISO/NSO) 36 36
Balance at Mar. 31, 2025 $ 7,435 $ 36,413 $ (35,271) $ 8,577
Balance (in Shares) at Mar. 31, 2025 20,000 1,600,000 16,038,376      
[1] 29,173,056 shares of Common Stock that may be issued on full exercise of the pre-funded warrants issued at $0.42 per share.
[2] Up to 1,085,714,550 shares of Common Stock that may be issued on exercise of the Series B warrants using the “zero exercise price option”.